Ms. Wendy Lynne Apgar, M.S., OTR, L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2127 Innerbelt Business Center Dr, Suite 107, Overland, MO 63114 Phone: 314-506-8800 Fax: 314-506-8880 |
News Archive
Madison Williams and Company, an integrated capital markets and advisory firm, announced today the formal launch of a focused Healthcare Investment Banking and Research business. Madison Williams recently completed a management buyout of the principal capital markets business from Sanders Morris Harris Group in December 2009. The new firm already has a leading franchise in the Energy sector, and is quickly establishing its presence in healthcare with key new hires.
"The developing world needs support for low-tech health innovations that do not compromise on effectiveness," journalist Priya Shetty writes in this SciDev.Net opinion piece, adding that, against the backdrop of global economic recession and shrinking research and development (R&D) budgets in many developing countries, "a new movement of 'frugal science' is taking hold, in which researchers are hunting for the most cost-effective health technologies for developing countries."
David H. Adams, MD, Marie-Jos-e and Henry R. Kravis Professor and Chairman of the Department of Cardiothoracic Surgery, Samin K. Sharma, MD, the Zena and Michael A. Weiner Professor and Director of the Cardiac Catheterization Laboratory, and Annapoorna S. Kini, MD, Associate Professor and Associate Director of the Cardiac Catheterization Laboratory at The Mount Sinai Medical Center, have performed the first implantation of the Medtronic CoreValve- Transcatheter Aortic Valve Prosthesis in the United States.
Traditional Chinese herbal medicines hold promise for slowing the progression from prediabetes to an official diabetes diagnosis, according to new research accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.
› Verified 5 days ago